There's been lots of MIS-UNDERSTOOD press about Rezulin (troglitazone) going off the market

August 1998

There's been lots of MIS-UNDERSTOOD press about Rezulin(troglitazone) going off the market.

It was taken off the market in England last year.

It was eliminated from the big NIH Diabetes PREVENTION Study.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

The new warnings about the GI drug Propulsid (cisapride)
Hypertension new findings are now coming to light regarding drug treatment for hypertension
Hypertension captopril (Capoten) reduces the risk of MI, stroke, and death in patients with hypertension
Cholesterol new 80 mg Zocor (simvastatin) tablet
Anticoagulants Lovenox (enoxaparin) at HOME
Gastroenterology two 10-day regimens for H. pylori
saw palmetto, provides SYMPTOMATIC benefit for men with benign prostatic hyperplasia (BPH)
Diabetes There's been lots of MIS-UNDERSTOOD press about Rezulin (troglitazone) going off the market
Diabetes developing new hand-held INHALERS that deliver insulin to the lungs
Women's Health Monistat 1, a new one-dose OTC product for vaginal candidiasis
Women's Health new OTC test for urinary tract infections
rifapentine (Priftin) for tuberculosis
Amoxil TABLETS
Omnicef (cefdinir), a new oral cephalosporin for children and adults
Migraine another "triptan" for migraines
Neurology & Pain NEW class of pain relievers